Increasing Global Burden of Prediabetes Drives Demand for Early Detection and Intervention Solutions

Prediabetes market was valued at $0.3 billion in 2024 and is projected to reach $1.1 billion by 2035, growing at a CAGR of 11.3 % during the forecast period (2025–2035). The increasing incidence of prediabetes in adults is becoming an essential public health issue, heavily contributing to the growth in demand for preventive healthcare interventions and fueling the growth of the global prediabetes market. Early identification and treatment are now top priorities, as prompt control can avert the development of type 2 diabetes and its complications. According to the Centers for Disease Control and Prevention (CDC), in May 2024, an estimated 97.6 million adults aged 18 years and over in the US had prediabetes, representing 38.0% of the adult population. Among those aged 65 years and older, an estimated 27.2 million (48.8%) older adults had prediabetes.  

Browse the full report description of “Prediabetes Market Size, Share & Trends Analysis Report by Drug Class (Biguanide (Metformin), Thiazolidinediones (TZDs), Glucagon-like Peptide-1 Agonists (GLP-1), SGLT2 Inhibitors, DPP-4 Inhibitors, and Others), by Route of Administration (Oral, and Injectable), and by Age Group (Children (12 to 18 Years), Adult (18 to 50 Years), and Elderly (Above 50 Years)) Forecast Period (2025-2035)” at https://www.omrglobal.com/industry-reports/prediabetes-market

The increased prevalence of prediabetes emphasises a significant public health problem, driving the need for early detection, intervention, and management solutions. The increasing burden has fuelled the expansion of the prediabetes market, which includes medications, medical devices, digital health technologies, and lifestyle intervention programs. Pharmaceutical firms are putting money into the creation of innovative treatments to hold back the progression of prediabetes to type 2 diabetes. Moreover, advancements in diagnostic technology, such as continuous glucose monitoring and biomarker-based screenings, are improving early detection rates. The fusion of artificial intelligence and big data analytics in predictive modeling is also complementing personalized treatment strategies.

Global Burden of Prediabetes

Source: National Center for Biotechnology Information (NCBI)

Market Coverage

• The market number available for – 2024-2035
• Base year- 2024
• Forecast period- 2025-2035
• Segment Covered-
  • By Drug Class
  • By Route of Administration
  • By Age Group
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Competitive Landscape - Abbott Laboratories, AstraZeneca, Eli Lilly and Co., Medtronic MiniMed, Inc., Nordisk A/S, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Prediabetes Market Report Segment

By Drug Class

• Biguanide (Metformin)
• Thiazolidinediones (TZDs)
• Glucagon-like Peptide-1 Agonists (GLP-1)
• SGLT2 Inhibitors
• DPP-4 Inhibitors
• Others

By Route of Administration

• Oral
• Injectable

By Age Group

• Children (12 to 18 Years)
• Adults (18 to 50 Years)
• Elderly (Above 50 Years)

Global Prediabetes Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/prediabetes-market